SCHOTT Pharma AG & Co. KGaA : Increasing optimism on FY 2024 while long-term drivers are intact
>More optimistic on FY 2024 as visibility increases - The most important topic of SCHOTT Pharma's H1 conference call last week was CFO Dr Almuth Steinkühler's more positive sales guidance for 2024. Previously the company limited the guidance to the low end of its 9-11% sales growth target for FY 2024 as FY 2023 came in stronger than anticipated and therefore comps were challenging. At the conference call, the CFO explicitly emphasised that the full range of the guidan...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.